[Plasma homocysteine concentration and its relationship with the development of preeclampsia. Effect of prenatal administration of folic acid].
The increase of plasmatic homocysteine (Hc) in pregnant women, who later develop preeclampsia/eclampsia, the cause of this increment and its pathogenic role in toxemia of pregnancy, are still controversial. The objectives of the present research were to determine the plasmatic He concentrations during the first and second trimesters of pregnancy and the effect of folic acid administration on these values, and in the prevention of preeclampsia. Ninety six pregnant women of low economic background were studied on the first prenatal consultation: 27 women in the first trimester of pregnancy and 59 in the second. After 8 hours of fasting, venous blood was extracted and each patient was provided with 1 mg folic acid tablets and instructed to ingest one tablet daily, and to come back to the laboratory after three months. Plasma homocysteine and serum folic acid were determined for each patient before and after the folic acid treatment, by using the IMX system (Abbott Lab) and radioimmunoassay, respectively. Basal homocysteine concentrations were 4.0 +/- 2.1 micromol/L and 4.8 +/- 2.1 micromol/L in the first and second trimesters respectively, with no significant modifications after three months of folic acid. Although the degree of desertion from the study was high, it was possible to determine the evolution of 65 pregnancies. Ten of them developed preeclampsia (15.4%). No significant differences were found in Hc concentrations, or the frequency of hyperhomocysteinemia in the different stages of pregnancy, between women with normal gestation and those who developed preeclampsia. The small sample size of these groups, preclude any valid conclusion, however the results do not suggest that Hc concentration or folic acid administration influence the development of toxemia of pregnancy.
Cátedra de Ginecología y Obstetricia, Escuela de Medicina, Universidad del Zulia, Maracaibo, Venezuela.
Marisol
M
Fernández
Gerardo
G
Fernández
Maria
M
Diez-Ewald
Enrique
E
Torres
Gilberto
G
Vizcaíno
Nelson
N
Fernández
Janeth
J
Narváez
Melvis
M
Arteaga-Vizcaíno
D000293:Adolescent; D000328:Adult; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D005865:Gestational Age; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000517:prevention & control; D011203:Poverty; D011225:Pre-Eclampsia / Q000097:blood* / Q000453:epidemiology / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000517:prevention & control*; D011264:Pregnancy Trimesters; D012959:Socioeconomic Factors
D006710:Homocysteine; D005492:Folic Acid